IMpassion130 Trial: Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer
Posted: Thursday, August 15, 2019
Adding atezolizumab to nanoparticle albumin-bound (nab)-paclitaxel provides an overall survival benefit of 7 months in patients with previously untreated PD-L1–positive advanced triple-negative breast cancer, according to the second interim overall survival analysis of the phase III trial IMpassion130. This is consistent with the first interim analysis. The research was presented by Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, and colleagues at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 1003).
“Patient-reported outcomes are comparable between both arms, which I think is a true reflection of the fact that the treatment is very well tolerated,” said Dr. Schmid in an interview with The ASCO Post.
The researchers treated 902 patients with previously untreated locally advanced or metastatic triple-negative breast cancer. Patients were randomly assigned to receive atezolizumab plus nab-paclitaxel or a placebo plus nab-paclitaxel. Atezolizumab or placebo was administered intravenously on days 1 and 15 of a 28-day cycle, and nab-paclitaxel, on days 1, 8, and 15. Treatment continued until disease progression. Patients were stratified by PD-L1 presence on tumor-infiltrating immune cells.
In the PD-L1–positive population, overall survival was 25 months with atezolizumab, compared with 18 months with the placebo—a statistically significant difference. In the intent-to-treat population, overall survival did not significantly differ between the two treatments.
As of the data cutoff of January 2019, 9% of patients in the atezolizumab arm and 3% in the placebo arm remained on treatment. A safety update 4.5 months later indicated that atezolizumab plus nab-paclitaxel was still tolerable.
Disclosure: The study authors’ disclosure information may be found at coi.asco.org.